2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-177623
    CpG-ODN c41 1228853-94-8
    CpG-ODN c41, an oligonucleotide, is an antagonist of TLR9.
    CpG-ODN c41
  • HY-177627
    Edifoligide 328538-04-1
    Edifoligide is a decoy oligonucleotide that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure
    Edifoligide
  • HY-177652
    Onvuzosiran 2982817-49-0 98%
    Onvuzosiran, a siRNA, is a prekallikrein synthesis reducer.
    Onvuzosiran
  • HY-177691
    CCI17464 325780-75-4 98%
    CCI17464 is a selective, orally active EP4 partial agonist with a pKi of 7.1. CCI17464 can be used in a Freund's complete adjuvant (FCA) acute rat inflammatory pain model and shows complete reversal of allergic reactions.
    CCI17464
  • HY-177712
    RORγt inverse agonist 36 1599530-54-7
    RORγt inverse agonist 36 (S configuration of Compound 16) is a RORγt inverse agonist. RORγt inverse agonist 36 can be used for the research of inflammation and immunology.
    RORγt inverse agonist 36
  • HY-177726
    UTPU trisodium 401618-61-9 98%
    UTPU trisodium (Compound 19) is a selective P2Y6R agonist with an EC50 of 0.4 μM. UTPU trisodium can activate the intracellular calcium signaling pathway mediated by P2Y6. UTPU trisodium can be used for the research of inflammation.
    UTPU trisodium
  • HY-177739
    Antifibrotic agent 2 1590409-23-6 98%
    Antifibrotic agent 2 (Compound 636) is a polycyclic pyridinone derivative with antifibrotic activity. Antifibrotic agent 2 reduces the pathological accumulation of fibrosis-related proteins such as fibronectin and collagen, prevents excessive fibrous connective tissue from depositing in organs or tissues, and reverses or delays the remodeling of tissue fibrosisby regulating the abnormal proliferation and activation of fibroblasts. Antifibrotic agent 2 can be used for research on pulmonary fibrosis.
    Antifibrotic agent 2
  • HY-177754
    IKZF2-degrader 3 2983841-46-7
    IKZF2-degrader 3 (compound 6) is a molecular glue IKZF2 degrader with a DC50 of 2.0 nM.
    IKZF2-degrader 3
  • HY-177762
    Pan-RAS-IN-8 3103594-37-9
    Pan-RAS-IN-8 (Page 152, third row, third from left to right) is a pan-RAS inhibitor. Pan-RAS-IN-8 blocks the binding of RAS to downstream effector molecules by forming a ternary complex, thereby inhibiting the activation of the MAPK and PI3K-AKT signaling pathways. Pan-RAS-IN-8 can be used for the research of cancer, inflammatory diseases and autoimmune diseases.
    Pan-RAS-IN-8
  • HY-177800
    ARC5690 sodium
    ARC5690 sodium is an anti-mouse P-selectin aptamer. ARC5690 bound to recombinant mouse P-selectin with a KD of approximately 15pM in vitro. ARC5690 showed a significant anti-inflammatory effect
    ARC5690 sodium
  • HY-177803
    Protein C aptamer sodium
    Protein C aptamer sodium is a 44mer-DNA aptamer that the anticoagulant functions of activated protein C. Activated protein C (APC) is a serine protease with anticoagulant, anti-inflammatory, and cytoprotective properties.
    Protein C aptamer sodium
  • HY-177804
    Thrombin aptamer sodium
    Thrombin aptamer is a 11mer-DNA aptamer that targets thrombin. Thrombin aptamer inhibites thrombin-catalysed fibrin-clot formation in vitro
    Thrombin aptamer sodium
  • HY-177809
    aptTNF-α sodium
    aptTNF-α sodium is a TNF-α-targeting aptamer that has tissue protective effect and systemic anti-inflammatory effect upon acute tissue injury using the mouse acute lung injury (ALI) and acute liver failure (ALF) models.
    aptTNF-α sodium
  • HY-177819
    DTA-64 sodium 98%
    DTA-64 sodium is a aptamer targeted DEK. It significantly reduces joint inflammation in zymosan-induced arthritis mouse model and greatly impairs the ability of neutrophils to form neutrophil extracellular traps (NETs). DEK is a secreted protein abundant
    DTA-64 sodium
  • HY-177834
    Liposomal Zinc 98%
    Liposomal Zinc is a specialized delivery system that encapsulates zinc compound within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of zinc. Zinc is an important trace element and plays a key role
    Liposomal Zinc
  • HY-177845
    Liposomal Resveratrol 98%
    Liposomal Resveratrol is a specialized delivery system that encapsulates resveratrol within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of resveratrol. Resveratrol is a polyphenol found in plants,
    Liposomal Resveratrol
  • HY-177847
    Liposomal Quercetin 98%
    Liposomal Quercetin is a specialized delivery system that encapsulates quercetin within tiny liposomes. These liposomes act as protective shells, enhancing the absorption and bioavailability of quercetin. Quercetin is a natural flavonoid with nutritional
    Liposomal Quercetin
  • HY-177878
    IMU-856 2303528-97-2
    IMU-856 is an orally active and systemic action SIRT6 small molecule regulator. IMU-856 effectively and selectively inhibits the deacetylase activity of SIRT6, while increasing the protein level of SIRT6. IMU-856 can restore intestinal barrier function and can be used for research on celiac disease.
    IMU-856
  • HY-177944
    DC-PGKI 2829198-49-2
    DC-PGKI is an orally active ATP-competitive PGK1 inhibitor(IC50 = 0.16 Μm, Kd = 99.08 nM). DC-PGKI stabilizes PGK1 in vitro and in vivo, and suppresses both glycolytic activity and the kinase function of PGK1. DC-PGKI-mediated inhibition of PGK1 leads to the accumulation of NRF2 (nuclear factor-erythroid factor 2-related factor 2, NFE2L2), which then translocates to the nucleus, binds to the proximal regions of IL-1β and IL-6 genes, and suppresses the LPS-induced expression of these genes. DC-PGKI can be used for the study of colitis.
    DC-PGKI
  • HY-177961
    α4β7 Integrin-IN-1 2417307-52-7 98%
    α4β7 Integrin-IN-1 (Example 356) is a potent inhibitor of α4β7 integrin (integrin). Its ability to block the interaction between α4β7 integrin and MadCAM-1 (EC50) is 0.05 nM. α4β7 Integrin-IN-1 can be used for the study of inflammatory bowel disease.
    α4β7 Integrin-IN-1
Cat. No. Product Name / Synonyms Application Reactivity